Navigation Links
FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Date:12/13/2010

olytic hepatitis) has been reported with PREZISTA/ritonavir. During the clinical development program (N=3063), hepatitis has been reported in 0.5% of patients receiving combination therapy with PREZISTA/ritonavir. Patients with preexisting liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities, including severe hepatic adverse events

Post-marketing cases of liver injury, including some fatalities, have been reported. A causal relationship with PREZISTA/ritonavir therapy has not been establishedAppropriate laboratory testing should be conducted prior to initiating therapy with PREZISTA/ritonavir and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pretreatment elevations of transaminases, especially during the first several months of PREZISTA/ritonavir treatment. Evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients on PREZISTA/ritonavir should prompt consideration of interruption or discontinuation of treatment


  • Severe Skin Reactions:  Severe skin reactions (0.4%), accompanied by fever and/or elevations of transaminases in some cases, Stevens-Johnson Syndrome (<0.1%), and toxic epidermal necrolysis (post-marketing experience) have been reported in patients receiving PREZISTA/ritonavir.  Discontinue PREZISTA/ritonavir immediately if signs or symptoms of severe skin reactions develop (including, but not limited to, severe rash or rash accompanied with fever, general malaise, fatigue, muscle or join aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia)  

  • In clinical trials (N=3063), rash (all grades, generally m
    '/>"/>

    SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)...   Mary,s Medicinals today announced that its ... Sponsor of Operation Grow4Vets , a national, nonpartisan ... and services to assist them in living with injuries ... , An ever-increasing number of medical studies ... treatment for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic ...
    (Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
    (Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
    Breaking Medicine Technology:Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
    ... and additional analyses from the Phase II portion of ... relaxin for the treatment of acute heart failure will ... meeting of the Heart Failure Association of the European ... M.D., professor of cardiology at the University of Brescia, ...
    ... Breast Cancer and Melanoma Studies - Conference Call to ... am BRANFORD, Conn., May 28 CuraGen Corporation ... for three data presentations from its ongoing clinical trials ... patients with advanced breast cancer and melanoma at the ...
    Cached Medicine Technology:Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
    (Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
    (Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
    (Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
    (Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
    (Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, Fancyflyingfox.com, ... special occasion clothes, has announced its latest designs of ... addition, all the new elegant outfits are offered with ... place an order before October 30 can enjoy this ... and great marketing strategies, it has become one of ...
    Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
    ... more than 600,000 people die of sudden cardiac arrest in ... heart attack or a heart rhythm disturbance. ,When medical ... in which the heart's main pumping chambers flutter wildly and ... survive to go home. ,About 30 percent of victims, ...
    ... sometimes switch to lower tar cigarettes in hopes of ... experience the consequences of higher tar cigarettes.// ,Non-filter cigarettes ... the United States and United Kingdom. A new study ... for people who smoke medium-tar cigarettes, low-tar cigarettes, or ...
    ... recent study researchers have created a model of the human ... may be a precursor to Alzheimer’s.// Myelin is ... allows for messages to be sent through the brain. However, ... promote the production of a toxic protein that attacks the ...
    ... destroys T-cells in the immune system. According to the ... 800,000 and 900,000 people living with HIV.// ,Previous ... be infected with HIV, and a new study helps ... of human foreskin. They found each sample contained cells ...
    ... doctors treat certain prostate cancer patients.The three strongest predictors ... grade, PSA level and pathologic stage. //The summation of ... system or a Gleason score (GS). The most common ... In a new study, researchers look to understand the ...
    ... molecule may have the potential to protect the kidneys ... ,For the study, mice were genetically engineered to ... factor (HGF) or another natural factor called parathyroid hormone-related ... functions, thus allowing the researchers to study how the ...
    Cached Medicine News:Health News:Vasopressin Found To Boost Survival In Sudden Cardiac arrest 2Health News:New Hope for Kidney Failure 2
    Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
    Near point card/newspaper 8 to 48 point type 5 1/2" X 8"....
    Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w...
    ... provides references to many common print sizes, from ... size. This provides the examiner a starting point ... with black ink on yellow styrene for increased ... 20/20. Other notations include Jaeger, M notation, lower ...
    Medicine Products: